Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Strontium signaling: molecular mechanisms and therapeutic implications in osteoporosis.

Saidak Z, Marie PJ.

Pharmacol Ther. 2012 Nov;136(2):216-26. doi: 10.1016/j.pharmthera.2012.07.009. Epub 2012 Jul 20. Review.

PMID:
22820094
2.

Osteoblasts play key roles in the mechanisms of action of strontium ranelate.

Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS.

Br J Pharmacol. 2009 Aug;157(7):1291-300. doi: 10.1111/j.1476-5381.2009.00305.x. Epub 2009 Jun 25.

3.

Strontium ranelate: a physiological approach for optimizing bone formation and resorption.

Marie PJ.

Bone. 2006 Feb;38(2 Suppl 1):S10-4. Epub 2006 Jan 24. Review.

PMID:
16439191
4.

The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.

Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.

Bone. 2011 Dec;49(6):1290-8. doi: 10.1016/j.bone.2011.08.031. Epub 2011 Sep 9.

PMID:
21925296
5.

The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways.

Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F, Wattel A, Kamel S, Terwilliger EF, Brown EM, Brazier M.

J Biol Chem. 2009 Jan 2;284(1):575-84. doi: 10.1074/jbc.M801668200. Epub 2008 Oct 16.

6.
7.

Strontium ranelate in osteoporosis.

Reginster JY.

Curr Pharm Des. 2002;8(21):1907-16. Review.

PMID:
12171530
8.

Strontium ranelate improves bone microarchitecture in osteoporosis.

Hamdy NA.

Rheumatology (Oxford). 2009 Oct;48 Suppl 4:iv9-13. doi: 10.1093/rheumatology/kep274. Review.

PMID:
19783592
9.

Strontium ranelate in osteoporosis and beyond: identifying molecular targets in bone cell biology.

Marie PJ.

Mol Interv. 2010 Oct;10(5):305-12. doi: 10.1124/mi.10.5.7. Review.

PMID:
21045244
10.

Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.

Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J.

Bone. 2011 Sep;49(3):559-67. doi: 10.1016/j.bone.2011.06.005. Epub 2011 Jun 12.

PMID:
21700005
11.

Strontium as therapy for osteoporosis.

Marie PJ.

Curr Opin Pharmacol. 2005 Dec;5(6):633-6. Epub 2005 Sep 23. Review.

PMID:
16183330
12.

Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms.

Caverzasio J.

Bone. 2008 Jun;42(6):1131-6. doi: 10.1016/j.bone.2008.02.010. Epub 2008 Feb 29.

PMID:
18378206
13.

Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate.

Fromigué O, Haÿ E, Barbara A, Petrel C, Traiffort E, Ruat M, Marie PJ.

J Cell Mol Med. 2009 Aug;13(8B):2189-99. doi: 10.1111/j.1582-4934.2009.00673.x.

14.

Future developments in osteoporosis therapy.

Ng KW.

Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):371-84.

PMID:
19857200
15.

An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts.

Rybchyn MS, Slater M, Conigrave AD, Mason RS.

J Biol Chem. 2011 Jul 8;286(27):23771-9. doi: 10.1074/jbc.M111.251116. Epub 2011 May 12.

16.

Strontium ranelate prevents the deleterious action of advanced glycation endproducts on osteoblastic cells via calcium channel activation.

Fernández JM, Molinuevo MS, Sedlinsky C, Schurman L, Cortizo AM, McCarthy AD.

Eur J Pharmacol. 2013 Apr 15;706(1-3):41-7. doi: 10.1016/j.ejphar.2013.02.042. Epub 2013 Mar 13.

PMID:
23499695
17.

[Partnership between academic research and industry to study a new anti-osteoporotic drug].

Mentaverri R, Wattel A, Lemaire-Hurtel AS, Kamel S, Blesius A, Brazier M.

Med Sci (Paris). 2005 Jun-Jul;21(6-7):663-8. Review. French.

18.

Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength.

Fonseca JE.

Rheumatology (Oxford). 2008 Jul;47 Suppl 4:iv17-19. doi: 10.1093/rheumatology/ken165. Review.

19.

The calcium-sensing receptor in bone metabolism: from bench to bedside and back.

Cianferotti L, Gomes AR, Fabbri S, Tanini A, Brandi ML.

Osteoporos Int. 2015 Aug;26(8):2055-71. doi: 10.1007/s00198-015-3203-1. Epub 2015 Jun 23. Review.

PMID:
26100412
20.

Potential anti-catabolic and anabolic properties of strontium ranelate.

Mentaverri R, Brazier M, Kamel S, Fardellone P.

Curr Mol Pharmacol. 2012 Jun;5(2):189-94. Review.

PMID:
21787286

Supplemental Content

Support Center